Ocugen to Present Phase 2 Clinical Data for OCU410 Gene Therapy in March 2026

Ocugen, Inc. (OCGN) has announced a scheduled webcast on March 24, 2026, to present clinical data from its Phase 2 ArMaDa trial. The trial evaluates OCU410, a modifier gene therapy designed to treat geographic atrophy (GA), a late-stage form of dry age-related macular degeneration. The event will feature insights from key opinion leaders (KOLs) alongside the company’s executive leadership team. This presentation aims to provide the investment and medical communities with a comprehensive look at the treatment's clinical efficacy and safety. Clinical trial readouts are significant catalysts for biotechnology firms, often driving stock volatility and investor interest. The announcement underscores Ocugen's progress in developing innovative solutions for ophthalmology.

Fontes:globenewswire.comfinancialcontent.comstocktitan.netaktiencheck.debenzinga.comtradingview.comainvest.cominsidermonkey.com